|
1
|
Oh WT, Yang YS, Xie J, Ma H, Kim JM, Park KH, Oh DS, Park-Min KH, Greenblatt MB, Gao G, Shim JH. WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. Mol Ther 2023; 31:435-453. [PMID: 36184851 PMCID: PMC9931550 DOI: 10.1016/j.ymthe.2022.09.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 08/14/2022] [Accepted: 09/28/2022] [Indexed: 11/07/2022] Open
Abstract
Treating osteoporosis and associated bone fractures remains challenging for drug development in part due to potential off-target side effects and the requirement for long-term treatment. Here, we identify recombinant adeno-associated virus (rAAV)-mediated gene therapy as a complementary approach to existing osteoporosis therapies, offering long-lasting targeting of multiple targets and/or previously undruggable intracellular non-enzymatic targets. Treatment with a bone-targeted rAAV carrying artificial microRNAs (miRNAs) silenced the expression of WNT antagonists, schnurri-3 (SHN3), and sclerostin (SOST), and enhanced WNT/β-catenin signaling, osteoblast function, and bone formation. A single systemic administration of rAAVs effectively reversed bone loss in both postmenopausal and senile osteoporosis. Moreover, the healing of bone fracture and critical-sized bone defects was also markedly improved by systemic injection or transplantation of AAV-bound allograft bone to the osteotomy sites. Collectively, our data demonstrate the clinical potential of bone-specific gene silencers to treat skeletal disorders of low bone mass and impaired fracture repair.
Collapse
Affiliation(s)
- Won-Taek Oh
- Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, 364 Plantation Street. LRB 217, Worcester, MA 01605, USA; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul 03722, Korea
| | - Yeon-Suk Yang
- Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, 364 Plantation Street. LRB 217, Worcester, MA 01605, USA
| | - Jun Xie
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Viral Vector Core, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA
| | - Hong Ma
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Viral Vector Core, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA
| | - Jung-Min Kim
- Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, 364 Plantation Street. LRB 217, Worcester, MA 01605, USA
| | - Kwang-Hwan Park
- Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul 03722, Korea
| | | | - Kyung-Hyun Park-Min
- Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY 10021, USA; Research Division, Hospital for Special Surgery, New York, NY 10021, USA
| | - Matthew B Greenblatt
- Research Division, Hospital for Special Surgery, New York, NY 10021, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
| | - Guangping Gao
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Viral Vector Core, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA.
| | - Jae-Hyuck Shim
- Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, 364 Plantation Street. LRB 217, Worcester, MA 01605, USA; Horae Gene Therapy Center, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, 368 Plantation Street AS6-2049, Worcester, MA 01605, USA.
| |
Collapse
|
|
2
|
Kim S, Ahn T, Han MH, Bae C, Oh DS. Wicking Property of Graft Material Enhanced Bone Regeneration in the Ovariectomized Rat Model. Tissue Eng Regen Med 2018; 15:503-510. [PMID: 30603573 DOI: 10.1007/s13770-018-0142-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2018] [Revised: 06/18/2018] [Accepted: 07/03/2018] [Indexed: 02/07/2023] Open
Abstract
Background Recruitment and homing cells into graft materials from host tissue is crucial for bone regeneration. Methods Highly porous, multi-level structural, hydroxyapatite bone void filler (HA-BVF) have been investigated to restore critical size bone defects. The aim was to investigate a feasibility of bone regeneration of synthetic HA-BVF compared to commercial xenograft (Bio-Oss). HA-BVF of 0.7 mm in average diameter was prepared via template coating method. Groups of animals (n = 6) were divided into two with normal (Sham) or induced osteoporotic conditions (Ovx). Subsequently, subdivided into three treated with HA-BVF as an experiment or Bio-Oss as a positive control or no treatment as a negative control (defect). The new bone formation was analyzed by micro-CT and histology. Results At 4 weeks post-surgery, new bone formation was initiated from all groups. At 8 weeks post-surgery, new bone formation in the HA-BVF groups was greater than Bio-Oss groups. Extraordinarily greater bone regeneration within the Ovx-HA group than Sham-Bio-Oss or Ovx-Bio-Oss group (p < 0.05). Conclusion This study suggests that the immediate wicking property of HA-BVF from host tissue activates a natural healing cascade without the addition of exogeneous factors or progenitor cells. HA-BVF may be an effective alternative for repairing bone defects under both normal and osteoporotic bone conditions.
Collapse
Affiliation(s)
- Seunghyun Kim
- 1College of Veterinary Medicine, Chonnam National University, 77 Yongbong-ro, Gwangju, 61186 Republic of Korea
| | - Taeho Ahn
- 1College of Veterinary Medicine, Chonnam National University, 77 Yongbong-ro, Gwangju, 61186 Republic of Korea
| | - Myung-Ho Han
- 2Department of Chemical Engineering, Kyungil University, 50 Gamasil-gil, Gyeongsan, 38428 Republic of Korea
| | - Chunsik Bae
- 1College of Veterinary Medicine, Chonnam National University, 77 Yongbong-ro, Gwangju, 61186 Republic of Korea
| | - Daniel S Oh
- 3Carroll Laboratory for Orthopedic Surgery, Columbia University, 650 West 168th Street, New York, NY 10032 USA
| |
Collapse
|